Minor cannabinoids are gaining increasing interest – pushed by both slowly growing consumer awareness and companies looking to develop further revenue streams from under-utilised products.
A number of claims have been made about the properties of various minor cannabinoids – some skirting dangerously close to the line of what is currently permitted and some going well over that health claims line.
In reality, the science behind the potential of minor cannabinoids is significantly behind where it should be – like much of the rest of the investigation into the benefits of cannabis – stymied by restrictions and stigma.
Nonetheless, some advances have been made. CBD-Intel has recently published a guide to the most commercially important minor cannabinoids, outlining what their potential effects could be and where the state of the science behind those claims is currently.
Feel free to submit your questions for our next blog post*
*Under CBD-Intel’s editorial discretion